Clik here to view.
Replicor、HBV／HDV同時感染のREP 301研究の結果がThe Lancet Gastroenterology &...
モントリオール （ビジネスワイヤ） — 慢性B型肝炎ウイルス（HBV）感染患者および慢性HBV/デルタ肝炎ウイルス（HDV）に同時感染した患者向けの治療薬に絞った開発に取り組む非公開バイオ製薬企業のReplicor Inc.は本日、REP 2139およびペグインターフェロンα-2a（pegIFN）の作用に関するREP 301研究の論文が、The Lancet Gastroenterology...
View ArticleClik here to view.
LivaNova和微创医疗宣布Rega起搏器获得中国国家食品药品监督管理总局批准
伦敦 (美国商业资讯)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova”)和微创医疗科学有限公司(HK:00853)（简称“微创医疗”）今天宣布，两家公司在上海组建的合资公司MicroPort Sorin Cardiac Rhythm Management Co. Ltd.（简称“MSC”或“合资公司”）生产的RegaTM起搏器系列获得国家食品药品监督管理总局批准。...
View ArticleClik here to view.
Seattle Genetics and Takeda Announce Publication in Blood of Final Long-Term...
BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan Seattle Genetics, Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced final data from the ADCETRIS...
View ArticleClik here to view.
CDISC Releases Therapeutic Area User Guide to Accelerate Development of...
AUSTIN, Texas The Clinical Data Interchange Standards Consortium (CDISC) is pleased to announce the release of a new Therapeutic Area Standard for Vaccines in the form of a User Guide for data...
View ArticleClik here to view.
3M Drives Global Design Scale with Announcement of 3M Design Center in Japan
ST. PAUL, Minn. 3M, the global innovation company long recognized for diversified technology and collaboration, announced the opening of a new 3M Design Center in Japan, a hub to accelerate the...
View ArticleClik here to view.
Promethera Biosciences and Shibuya Announce Strategic Collaboration to...
MONT-SAINT-GUIBERT, Belgium & KANAZAWA, ISHIKAWA, Japan Promethera Biosciences SA, a global innovator in cell-based medicines, and Shibuya Corporation (6340:Tokyo Stock Exchange) announced today...
View ArticleClik here to view.
Heptares Founder Richard Henderson Receives Nobel Prize in Chemistry 2017 for...
LONDON & TOKYO Heptares Therapeutics (“Heptares”), a wholly owned subsidiary of Sosei Group Corporation (“Sosei”; TOKYO Mothers Index: 4565), is delighted that one of its founders, Richard...
View ArticleClik here to view.
22ndセンチュリーのスペクトラム研究用紙巻きたばこを使用した第3相研究で、超低ニコチンへの即時の低減がタバコの有害性を最も減らし得ることを証明
米ニューヨーク州クラレンス （ビジネスワイヤ） — タバコの有害性低減に傾注する植物バイオテクノロジー企業の22ndセンチュリー・グループ（NYSE American:...
View ArticleClik here to view.
Clik here to view.
GNI Group Announces Clearance of Investigational New Drug (IND) by FDA for...
TOKYO GNI Group Ltd., (TOKYO:2160) announced that GNI USA, Inc. (“GNI USA”), the wholly-owned subsidiary of GNI Group, had received U.S. FDA clearance on September 29 for the Investigational New...
View ArticleClik here to view.
Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin...
BOTHELL, Wash. & TOKYO Seattle Genetics, Inc. (NASDAQ: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced dosing of the first patient...
View ArticleClik here to view.
Orthocell Appoints Surgical Specialties as Exclusive Distributor
PERTH, Australia Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce it has appointed Surgical Specialties Pty Ltd (Surgical Specialties)...
View ArticleClik here to view.
Avita Medical A$16.9 Million Capital Raising
VALENCIA, Calif. & PERTH, Australia & LONDON Avita Medical (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specialising in the treatment of wounds and skin defects, is undertaking...
View ArticleClik here to view.
Innovus Pharmaceuticals Expands Its International Proprietary Product Patent...
SAN DIEGO Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company...
View ArticleClik here to view.
Cogstate Announces First U.S. Deployment of the Cognigram™ System at the...
BOSTON The cognitive science company, Cogstate today announced the commercial deployment of its Cognigram™ digital cognitive assessment system at the University of Notre Dame. This placement...
View ArticleClik here to view.
和铂医药宣布，已授权信达生物制药使用其全人源单克隆抗体转基因小鼠平台开发多种全人源单克隆抗体新药
中国上海，荷兰鹿特丹和美国马萨诸塞州剑桥 和铂医药（Harbour BioMed）宣布，已授权一家中国优秀的创新型生物制药公司信达生物制药（Innovent Biologics, Inc.）使用其拥有全球专利技术的H2L2转基因小鼠平台，开发多领域的全人源单克隆抗体创新药物。...
View ArticleClik here to view.
Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement...
SHANGHAI & ROTTERDAM, The Netherlands & CAMBRIDGE, Mass. Harbour BioMed announced today that it has licensed its patented H2L2 transgenic mouse platform for generating fully human...
View ArticleClik here to view.
Shionogi Inc. and Purdue Pharma L.P. Announce U.S. Availability of Symproic®...
OSAKA, Japan & FLORHAM PARK, N.J. & STAMFORD, Conn. Shionogi Inc. and Purdue Pharma L.P. announced today that Symproic® (naldemedine) 0.2 mg tablets are now available throughout the United...
View ArticleClik here to view.
Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary...
PARIS Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and its partner Exelixis (NASDAQ: EXEL) today announced that its global phase 3 CELESTIAL trial met its primary endpoint of overall survival...
View ArticleClik here to view.
Novocure Announces Data Presentations at the IASLC 18th World Conference on...
ST. HELIER, Jersey Novocure (NASDAQ: NVCR) announced today five data presentations at the International Associations for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer,...
View Article